gemfibrozil has been researched along with Cardiovascular Diseases in 34 studies
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effect of insulin resistance and the benefit of the fibrate, gemfibrozil, on the incidence of major cardiovascular events in subjects with low HDL cholesterol and a broad range of triglyceride values who participated in the Veterans Affairs High Density Lipoprotein Intervention Trial (VA-HIT)." | 5.10 | Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). ( Anderson, JW; Collins, D; Elam, MB; Faas, FH; Robins, SJ; Rubins, HB; Schaefer, EJ, 2003) |
| " Of all the medications currently available, the fibric acid derivatives have a cholesterol lowering profile that is most likely to be effective in obese children with the high TG/low HDL phenotype and data from a recently published study of gemfibrozil in children with metabolic syndrome are promising." | 4.89 | Challenges in the pharmacologic management of obesity and secondary dyslipidemia in children and adolescents. ( Jellerson, KD; Kennedy, MJ; Snow, MZ; Zacchetti, ML, 2013) |
| "Gemfibrozil treatment was associated with 3% to 6% decreases in the small, lipid-poor prebeta-1 HDL and in the large, lipid-rich alpha-1 and alpha-2 HDL and with increases in the small alpha-3 (3%) and prealpha-3 (16%) HDLs." | 2.73 | Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. ( Asztalos, BF; Bloomfield, HE; Collins, D; Horvath, KV; Robins, SJ; Schaefer, EJ, 2008) |
| "Gemfibrozil is a lipid-modifying agent that belongs to the fibric acid derivative class." | 2.53 | Gemfibrozil in Combination with Statins-Is It Really Contraindicated? ( Morris, PB; Saseen, JJ; Wiggins, BS, 2016) |
| "Identification and treatment of the metabolic syndrome is of enormous public health importance because it is associated with a marked elevation in coronary heart disease risk and affects nearly 25% of adults in the United States." | 2.42 | Fibrates for treatment of the metabolic syndrome. ( Maki, KC, 2004) |
| " Recently, a new tablet formulation of micronised fenofibrate has become available with greater bioavailability than the older capsule formulation." | 2.41 | Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. ( Keating, GM; Ormrod, D, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 2 (5.88) | 18.2507 |
| 2000's | 23 (67.65) | 29.6817 |
| 2010's | 7 (20.59) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Kayıkçıoğlu, M | 1 |
| Shahbazova, S | 1 |
| İbrahimov, F | 1 |
| Can, LH | 1 |
| Kennedy, MJ | 1 |
| Jellerson, KD | 1 |
| Snow, MZ | 1 |
| Zacchetti, ML | 1 |
| Wang, D | 1 |
| Liu, B | 1 |
| Tao, W | 1 |
| Hao, Z | 1 |
| Liu, M | 1 |
| Wiggins, BS | 1 |
| Saseen, JJ | 1 |
| Morris, PB | 1 |
| Béliard-Lasserre, S | 1 |
| Jakob, T | 1 |
| Nordmann, AJ | 1 |
| Schandelmaier, S | 1 |
| Ferreira-González, I | 1 |
| Briel, M | 1 |
| McBride, P | 1 |
| Abourbih, S | 1 |
| Filion, KB | 1 |
| Joseph, L | 1 |
| Schiffrin, EL | 1 |
| Rinfret, S | 1 |
| Poirier, P | 1 |
| Pilote, L | 1 |
| Genest, J | 1 |
| Eisenberg, MJ | 1 |
| Devendra, GP | 1 |
| Whitney, EJ | 1 |
| Krasuski, RA | 1 |
| Bloomgarden, ZT | 1 |
| Drexler, A | 1 |
| Keating, GM | 1 |
| Ormrod, D | 1 |
| Robins, SJ | 4 |
| Rubins, HB | 1 |
| Faas, FH | 1 |
| Schaefer, EJ | 3 |
| Elam, MB | 1 |
| Anderson, JW | 1 |
| Collins, D | 5 |
| Maki, KC | 1 |
| Tonelli, M | 1 |
| Robins, S | 1 |
| Bloomfield, H | 1 |
| Curhan, GC | 1 |
| Ascaso, JF | 1 |
| Fernández-Cruz, A | 1 |
| González Santos, P | 1 |
| Hernández Mijares, A | 1 |
| Mangas Rojas, A | 1 |
| Millán, J | 1 |
| Felipe Pallardo, L | 1 |
| Pedro-Botet, J | 1 |
| Pérez-Jiménez, F | 1 |
| Pía, G | 1 |
| Pintó, X | 1 |
| Plaza, I | 1 |
| Rubiés-Prat, J | 1 |
| Sigal, R | 2 |
| Malcolm, J | 2 |
| Meggison, H | 1 |
| März, W | 1 |
| Rosenson, RS | 1 |
| Kon, YC | 1 |
| Tai, ES | 1 |
| O'Connor, JJ | 1 |
| Bloomfield, HE | 3 |
| Ordovas, JM | 1 |
| Brousseau, ME | 1 |
| Barter, PJ | 1 |
| Rye, KA | 1 |
| Arnaout, A | 1 |
| Calkin, AC | 1 |
| Allen, TJ | 1 |
| Lassila, M | 1 |
| Tikellis, C | 1 |
| Jandeleit-Dahm, KA | 1 |
| Thomas, MC | 1 |
| Bouhlel, MA | 1 |
| Staels, B | 1 |
| Chinetti-Gbaguidi, G | 1 |
| Asztalos, BF | 2 |
| Horvath, KV | 1 |
| Nelson, JJ | 1 |
| Brinton, EA | 1 |
| Gault, MH | 1 |
| Longerich, LL | 1 |
| Purchase, L | 1 |
| Harnett, J | 1 |
| Breckenridge, C | 1 |
| Rader, DJ | 1 |
| Haffner, SM | 1 |
| Durrington, P | 1 |
| Faergeman, O | 1 |
| Wright, JM | 1 |
| Puil, L | 1 |
| Bassett, CL | 1 |
| Nerbrand, C | 1 |
| Nyberg, P | 1 |
| Nordström, L | 1 |
| Samsioe, G | 1 |
18 reviews available for gemfibrozil and Cardiovascular Diseases
| Article | Year |
|---|---|
Challenges in the pharmacologic management of obesity and secondary dyslipidemia in children and adolescents.
Topics: Adolescent; Cardiovascular Diseases; Child; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Fibri | 2013 |
Fibrates for secondary prevention of cardiovascular disease and stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Caus | 2015 |
Gemfibrozil in Combination with Statins-Is It Really Contraindicated?
Topics: Cardiovascular Diseases; Drug Combinations; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase | 2016 |
Fibrates for primary prevention of cardiovascular disease events.
Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans | 2016 |
Triglycerides and risk for coronary artery disease.
Topics: Alcohol Drinking; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Gemfibrozil; Hydroxym | 2008 |
Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.
Topics: Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Fe | 2009 |
Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Topics: Cardiovascular Diseases; Databases, Bibliographic; Diabetes Mellitus, Type 2; Drug Delivery Systems; | 2002 |
Fibrates for treatment of the metabolic syndrome.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hyp | 2004 |
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Fenofibrate; Gemfibrozil; Human | 2004 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Corona | 2004 |
Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Gemfibrozil; Humans; Hypoli | 2005 |
Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?
Topics: Cardiotonic Agents; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Gemfibrozil; Humans; | 2006 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Clopid | 2006 |
Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Clinical Trials as Topic; Fenofibrate; Gemfib | 2008 |
Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Diabetic Angiopathies; D | 2008 |
Role of fibrates in the management of hypertriglyceridemia.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Gemfibrozil; H | 1999 |
Hypertriglyceridemia and the fibrate trials.
Topics: Bezafibrate; Cardiovascular Diseases; Clinical Trials as Topic; Female; Gemfibrozil; Humans; Hypertr | 2000 |
Analysis of serious adverse events. Lipid-lowering therapy revisited.
Topics: Cardiovascular Diseases; Clofibric Acid; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; | 2002 |
6 trials available for gemfibrozil and Cardiovascular Diseases
| Article | Year |
|---|---|
Impact of increases in high-density lipoprotein cholesterol on cardiovascular outcomes during the armed forces regression study.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholestyramine Res | 2010 |
Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).
Topics: Body Constitution; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Ty | 2003 |
Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency.
Topics: Aged; Cardiovascular Diseases; Creatinine; Gemfibrozil; Humans; Hypolipidemic Agents; Incidence; Kid | 2004 |
The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT).
Topics: Alleles; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus; Gemfi | 2006 |
Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
Topics: Cardiovascular Diseases; Coronary Disease; Gemfibrozil; Humans; Hypertension; Hypolipidemic Agents; | 2008 |
Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides.
Topics: Administration, Oral; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Estr | 2002 |
10 other studies available for gemfibrozil and Cardiovascular Diseases
| Article | Year |
|---|---|
Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort.
Topics: Adult; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cost of Illness; Di | 2020 |
[Fibrates: their prescription must be restricted].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Prescriptions; Fenofibrate; Fibric Acids; F | 2015 |
Fibrate use in diabetes: new concepts.
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Mellitus; Fenofibrate; Fibric Acids; Gemfibrozil; Hum | 2011 |
[Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mell | 2005 |
High-density lipoprotein cholesterol: ready for prime time?
Topics: Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Ch | 2005 |
Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Cell Adhesion; | 2007 |
Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Apolipoproteins B; Cardiovascular Diseases; Ch | 2008 |
Consensus conference: Treatment of hypertriglyceridemia.
Topics: Body Weight; Cardiovascular Diseases; Clofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipopro | 1984 |
Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apolipoprotein B-100; Apolipoproteins A; Apolipoproteins | 1995 |
A case for lipid-lowering?
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Dise | 2000 |